Chemicals group Wacker Chemie and construction firm Exyte have broken ground on mRNA competence centre at the Halle Biotech site in the Weinberg Campus technology park in Germany.
For this $103m project, Wacker Chemie has appointed Exyte as engineering, procurement, construction and qualification contract partner and general contractor.
Go deeper with GlobalData
All work relating to the construction project is provided by Exyte or by subcontractors on behalf of Exyte.
Exyte will be responsible for architectural design, technical building infrastructure and engineering of the complete plant and delivery of the processing plant, automation, commissioning and qualification.
At the new competence centre, Wacker will produce active ingredients based on messenger ribonucleic acid (mRNA) used in coronavirus vaccines and in medicinal products for the treatment of cancer amongst others.
Out of the total 7,400m2 gross floor area, 1,600m2 will be allocated for clean room, and four new production lines.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe German government will pay some annual fee to get some part of the capacity for its pandemic preparedness programme, while the rest will be used by Wacker to cater to customers developing other uses based on the mRNA technology.
The Wacker Group focuses its biopharmaceuticals activities within Wacker Biotech, which is a full-service provider for microbial manufacturing of pharmaceutical proteins.
Exyte CEO Dr. Wolfgang Büchele said: “We are delighted to support WACKER in planning, building, and qualifying the new facility with our extensive expertise in the construction of highly complex, high-quality pharmaceutical production facilities. We are making an important contribution towards producing cutting-edge mRNA therapeutics, both for personalized medicine and for the mass market, and are thus driving medical progress.”
Wacker Biotech managing director Melanie Käsmarker said: “The manufacture of pharmaceutical actives is subject to the highest standards. As such, the requirements for plant construction are just as high. In Exyte, we have the perfect partner for this project.”
The new building is expected to be completed and production to commence in under 24 months.
Exyte will use the proven ExyCell system for the rapid, modular construction of biopharma production facilities.
—————————————————————————————————————-
Image: Rendering of the mRNA competence center at the Wacker Biotech site in Halle. Credit: Exyte/Wacker Chemie AG/PRNewswire
